The protocol for this investigation provides a feasibility tool that may facilitate the measurement of a biomarker of mGluR5 expression to conduct rigorously designed clinical trials of FXS [2,40,41] and perhaps other subtypes of ASD [42]. This evidence concerns the gene GRM5 and fragile X syndrome.